<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180205</url>
  </required_header>
  <id_info>
    <org_study_id>2009-017010-68</org_study_id>
    <nct_id>NCT01180205</nct_id>
  </id_info>
  <brief_title>Telmisartan, Amlodipine and Flow Mediated Dilation</brief_title>
  <acronym>TEAMSTAprotect</acronym>
  <official_title>A TElmisartan and AMlodipine STudy to Assess the Cardiovascular PROTECTive Effects as Measured by Endothelial Dysfunction in Hypertensive at Risk Patients Beyond Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To show superior effects of the combination Telmisartan and Amlodipine (T and A) vs&#xD;
      Olmesartan and Hydrochlorothiazide (O and HCTZ) on endothelial dysfunction as measured by&#xD;
      flow mediated dilation (FMD) in hypertensive at risk patients beyond bloodpressure BP (equal&#xD;
      BP in both arms; target BP &lt;140/90 mmHg (&lt;130/80 mmHg for renally impaired and/ or diabetic&#xD;
      patients). To investigate the effects of T and A vs O and HCTZ in reducing arterial stiffness&#xD;
      and carotid atherosclerotic plaques.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IV, randomised, double-blind, forced- titration, active controlled,&#xD;
      mono-center study to primarily compare the effects on endothelial function of the combination&#xD;
      of telmisartan and amlodipine versus olmesartan and hydrochlorothiazide in hypertensive&#xD;
      patients at risk beyond blood pressure. Additionally, key secondary endpoints for this trial&#xD;
      are the changes in plaque and intima media complex echogenicity and the change in arterial&#xD;
      stiffness after 26 weeks of treatment.&#xD;
&#xD;
      576 patients will be included in the study after a screening period of two weeks and then&#xD;
      randomised in one of the two treatment groups. Pretreatment with ARBs, ACE-Inhibitors,&#xD;
      amlodipine and diuretics will be stopped last day before visit 2. At visit 2 the treatment&#xD;
      with either telmisartan and amlodipine or olmesartan and hydrochlorothiazide starts, so that&#xD;
      no medication is stopped without having been replaced by the study medication. After two&#xD;
      weeks treatment all patients will be up-titrated and having the maintenance dose for the&#xD;
      following 24 weeks. The trial will be performed at one center in Germany with access to&#xD;
      patients with hypertension. Patients will be recruited from the Department of Cardiology of&#xD;
      the university Mainz. There will be a promotion flyer and an information booklet about the&#xD;
      study for cardiologists practicising near Mainz, who like to sent their patient to the study&#xD;
      center. Sponsor of the trial is the university Mainz.&#xD;
&#xD;
      Stefan Blankenberg, MD has been designated as Principal Investigator for this national,&#xD;
      mono-center trial.&#xD;
&#xD;
      The study will be completed when the last patient had his last visit and the telephone follow&#xD;
      - up two weeks later will be performed. This latest patient contact is defined as end of&#xD;
      trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FMD flow mediated dilation</measure>
    <time_frame>baseline</time_frame>
    <description>The overall mean improvement following 26 weeks of treatment in FMD as measured by the change from Visit 2 for T80/A10 is equal to O40/H25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FMD</measure>
    <time_frame>after 26 weeks</time_frame>
    <description>The overall mean improvement following 26 weeks of treatment in FMD as measured by the change from Visit 2 for T80/A10 is equal to O40/H25.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echogenicity</measure>
    <time_frame>baseline</time_frame>
    <description>To investigate the effects of T and A vs O and HCTZ on grayscale median of carotid atherosclerotic plaques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial stiffness</measure>
    <time_frame>baseline</time_frame>
    <description>To investigate the effects of T and A vs O and HCTZ in reducing arterial stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial stiffness</measure>
    <time_frame>after 26 weeks</time_frame>
    <description>To investigate the effects of T and A vs O and HCTZ in reducing arterial stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echogenicity</measure>
    <time_frame>after 26 weeks</time_frame>
    <description>To investigate the effects of T and A vs O and HCTZ on grayscale median of carotid atherosclerotic plaques</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">576</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>T/A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan + Amlopidpine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>O/HCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olmesartan + Hydrochlorothiazide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)</description>
    <arm_group_label>T/A</arm_group_label>
    <other_name>MICARDIS® (Telmisartan)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks</description>
    <arm_group_label>T/A</arm_group_label>
    <other_name>Norvasc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
    <description>Olmesartan 40 mg po for 26 weeks</description>
    <arm_group_label>O/HCT</arm_group_label>
    <other_name>Olmetec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks</description>
    <arm_group_label>O/HCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to provide written informed consent in accordance with Good Clinical Practice&#xD;
             and local legislation.&#xD;
&#xD;
          -  Age 35 and older.&#xD;
&#xD;
          -  Male and female, treated and treatment-naive patients with uncontrolled hypertension&#xD;
             (defined as 20/10 mmHg above target BP of &lt;140/90 mmHg [&lt;130/80 mmHg for renally&#xD;
             impaired and/ or diabetics patients])&#xD;
&#xD;
          -  Male and female treated patients with controlled hypertension (defined as target BP &lt;&#xD;
             140/90 mmHg [ &lt; 130/80 mmHg for renally impaired and/ or diabetics patients])&#xD;
&#xD;
          -  &gt; 3 cardiovascular risk factors CVRFs and/or metabolic syndrome and/or diabetes&#xD;
             mellitus and/or end organ damage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pretreatment with Telmisartan within the last 3 months.&#xD;
&#xD;
          2. Pretreatment with Amlodipine, Diuretics and AT1Blocker/ACEInhibitor within the last 3&#xD;
             months&#xD;
&#xD;
          3. Myocardial infarction within last 6 months.&#xD;
&#xD;
          4. Previous stroke or hemodynamically relevant stenosis of carotic arteria (&gt;70%).&#xD;
&#xD;
          5. Previous cardial or peripheral bypass surgery within last 6 months.&#xD;
&#xD;
          6. PAD stadium III - IV n.F.&#xD;
&#xD;
          7. Chronic heart failure NYHA III- IV.&#xD;
&#xD;
          8. Unstable angina.&#xD;
&#xD;
          9. Known intolerance to angiotensin receptor blockers, diuretics or dihydropyridine&#xD;
             calcium channel blocker.&#xD;
&#xD;
         10. Pre-menopausal women (last menstruation ≤1 year prior to signing informed consent)&#xD;
             who:&#xD;
&#xD;
               1. are not surgically sterile; or&#xD;
&#xD;
               2. are nursing, or&#xD;
&#xD;
               3. are pregnant, or&#xD;
&#xD;
               4. are of childbearing potential and are NOT practicing acceptable methods of birth&#xD;
                  control, or do NOT plan to continue practicing an acceptable method throughout&#xD;
                  the trial.&#xD;
&#xD;
                  The only acceptable methods of birth control are:&#xD;
&#xD;
               5. Intra-Uterine Device (IUD)&#xD;
&#xD;
               6. Oral&#xD;
&#xD;
               7. implantable or injectable contraceptives&#xD;
&#xD;
               8. Estrogen patch&#xD;
&#xD;
               9. Hormonal birth control should have been in use for at least three months before&#xD;
                  the study and continue at least until the next menstrual period after completing&#xD;
                  the study&#xD;
&#xD;
         11. Night shift workers who routinely sleep during the daytime and whose work hours&#xD;
             include midnight to 4:00 a.m.&#xD;
&#xD;
         12. Known or suspected secondary hypertension (e.g., renal artery stenosis or&#xD;
             phaeochromocytoma)&#xD;
&#xD;
         13. Mean in-clinic seated cuff SBP ≥180 mmHg and/or DBP ≥110 mmHg&#xD;
&#xD;
         14. Renal dysfunction as defined by the following laboratory parameters:&#xD;
&#xD;
         15. Serum creatinine &gt;3.0 mg/dL (or &gt;265 μmol/L) and/or known estimated creatinine&#xD;
             clearance of &lt;30 ml/min and/or clinical markers of severe renal impairment.&#xD;
&#xD;
         16. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney,&#xD;
             post-renal transplant patients or patients with only one kidney&#xD;
&#xD;
         17. Clinically relevant hypokalemia or hyperkalemia (i.e., &lt;3.0 or &gt;5.5 mEq/L, may be&#xD;
             rechecked for suspected error in result)&#xD;
&#xD;
         18. Uncorrected sodium or volume depletion&#xD;
&#xD;
         19. Primary aldosteronism&#xD;
&#xD;
         20. Hereditary fructose intolerance&#xD;
&#xD;
         21. Biliary obstructive disorders (e.g., cholestasis) or hepatic insufficiency&#xD;
&#xD;
         22. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or&#xD;
             other clinically relevant cardiac arrhythmias as determined by the Investigator&#xD;
&#xD;
         23. Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease,&#xD;
             aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve&#xD;
&#xD;
         24. Patients whose diabetes has not been stable and controlled for at least the past three&#xD;
             months as defined by an HbA1C ≥10%&#xD;
&#xD;
         25. Patients who have previously experienced symptoms characteristic of angioedema during&#xD;
             treatment with ACE inhibitors or angiotensin-II receptor antagonists&#xD;
&#xD;
         26. History of drug or alcohol abuses within six months prior to signing the informed&#xD;
             consent form&#xD;
&#xD;
         27. Concomitant administration of any medications known to affect BP, except medications&#xD;
             allowed by the protocol&#xD;
&#xD;
         28. Any investigational drug therapy within one month of signing the informed consent&#xD;
&#xD;
         29. Known contraindication to any component of the trial drugs (telmisartan, amlodipine,&#xD;
             olmesartan, hydrochlorothiazide)&#xD;
&#xD;
         30. History of non-compliance or inability to comply with prescribed medications or&#xD;
             protocol procedures&#xD;
&#xD;
         31. Any other clinical condition which, in the opinion of the investigator, would not&#xD;
             allow safe completion of the protocol and safe administration of the trial medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Blankenberg, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mainz, II.Medizinische Klinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <last_update_submitted>July 11, 2011</last_update_submitted>
  <last_update_submitted_qc>July 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof.Dr.med.S.Blankenberg</name_title>
    <organization>Departement for cardiology</organization>
  </responsible_party>
  <keyword>FMD</keyword>
  <keyword>hypertension</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Amlodipine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

